Session Information

ACLC 2018

IASLC Asia Conference on Lung Cancer 2018

Access Abstracts and Powerpoint Slides to select presentations that took place during the IASLC Asia Conference on Lung Cancer 2018 in Guangzhou, China from November 8 - 10, 2018. This package is available for no charge to active IASLC Members.
Presentation Date(s):
- November 8 - 10, 2018
- Total Presentations: 137
Register to Attend WCLC Switch to Virtual Meeting
Enter Virtual Meeting Access Code

All Days Wednesday
November 7 Wed
Nov 7 Thursday
November 8 Thu
Nov 8 Friday
November 9 Fri
Nov 9 Saturday
November 10 Sat
Nov 10

Filter Results:

Show Only CME Accredited Sessions

28124

+
Best abstracts selected from submissions 4
- 10:50 - 11:30
- 11/09/2018
- Location: Crystal Ballroom
- Type: Oral Session
- Track:
- 28226
  
  +
  
  OA07 - Clinical Characterization Of ERBB2 Exon 20 Insertions and Heterogeneity of Outcomes to Afatinib in Chinese Lung Cancers
  
  16:50 - 17:00 | Presenter: Z. Liu, Y. Hu, L. Wu, J. Cao, Z. Yang, C. Zhou, L. Cao, H. Wu, H. Shen, M. Jin, Y. Zhang, J. Xiang, K. Ma, B. Li, T. Zhang, X. Mao
  Abstract
  
  Loading...
- 28225
  
  +
  
  OA08 - Efficacy and Safety of Sintilimab Combined with 1st Line Chemotherapy in Advanced Squamous Cell Non-small Cell Lung Cancer
  
  17:00 - 17:10 | Presenter: K. Ying, N. Xu, H. Jiang, Y. Liu, H. Zhou, S. Wang
  Abstract
  
  Loading...
28126

+
Best abstracts selected from submissions 5
- 16:20 - 17:00
- 11/09/2018
- Location: Crystal Ballroom 1
- Type: Oral Session
- Track:
- 28230
  
  +
  
  OA09 - Preliminary Clinical Activity of Repotrectinib (TPX-0005) in Advanced ROS1 Fusion-Positive Non-Small Cell Lung Cancer
  
  22:20 - 22:30 | Presenter: S. Ou, B.C. Cho, D. Kim, A. Drilon, J. Lee, J. Lin, V. Zhu, M. Ahn, D.R. Camidge, S. Shanna Stopatschinskaja, J. Liu, J. Cui, D. Hyman, R. Doebele, A. Shaw
  Abstract
  
  Loading...
- 28229
  
  +
  
  OA10 - CheckMate 078: Patient-Reported Outcomes (PROs) With Nivolumab vs Docetaxel in Advanced Non-Small Cell Lung Cancer (NSCLC)
  
  06:30 - 06:40 | Presenter: Y. Wu, J. Chang, L. Zhang, H. Tu, L. Wu, J. Feng, S. Lu, C. Zhou, J. Wang, T. Mok, F. Taylor, B. Mossman, J. Penrod, R. Lawrance, S. Blum, P.F. Wang, Y. Cheng
  Abstract
  
  Loading...
28127

+
Best abstracts selected from submissions 6
- 16:20 - 17:00
- 11/09/2018
- Location: Crystal Ballroom 3
- Type: Oral Session
- Track:
- 28231
  
  +
  
  OA11 - First-Line Nivolumab + Ipilimumab in Asian Patients With Advanced NSCLC and High TMB (?10 mut/Mb): Results From CheckMate 227
  
  22:20 - 22:30 | Presenter: K. Park, J. Lee, H. Sakai, K. Lee, Y. Ohe, S. Kim, T. Fukuhara, J. Kang, C. Yu, H. Daga, K. Hotta, T. Yokoyama, H. Tanaka, M. Takeda, M. Hellmann, J. Sheng, F. Nathan, R. Yang, M. Nishio
  Abstract
  
  Loading...
- 28232
  
  +
  
  OA12 - A Phase I Study of Novel Bcl-2/Bcl-xL Inhibitor APG-1252 in Patients with Advanced SCLC
  
  22:30 - 22:40 | Presenter: J Ji
  Abstract
  
  Loading...
28125

+
Best abstracts selected from submissions 7
- 16:20 - 17:00
- 11/09/2018
- Location: Jade Ballroom
- Type: Oral Session
- Track:
- 28228
  
  +
  
  OA13 - High-dose Icotinib in Advanced NSCLC with EGFR 21 L858R Mutation: A Randomized, Open-Label Phase II Study
  
  22:20 - 22:30 | Presenter: X. Li, L. Zhang, D. Jiang, Y. Wang, A. Zang, C. Ding, M. Zhao, W. Su, Y. Zhang, D. Zhong, J. Wu, G. An, C. Zhang, X. Hu, G. Cheng, H. Wang, Z. Han, X. He, J. Liu, L. Liang, S. Zhang
  Abstract
  
  Loading...
- 28227
  
  +
  
  OA14 - Phase 2 Study: Tepotinib + Gefitinib in MET+/Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
  
  22:30 - 22:40 | Presenter: Y. Cheng, J. Zhou, S. Lu, Y. Zhang, J. Zhao, H. Pan, Y. Chen, C. Chian, R. Bruns, A. Johne, J. Scheele, Y. Wu
  Abstract
  
  Loading...
28251

+
Parallel Session 1 - New strategy for neoadjuvant and adjuvant therapy
- 16:20 - 17:00
- 11/09/2018
- Location: Jade Ballroom
- Type: Oral Session
- Track:
- 28252
  
  +
  
  New perspectives on neoadjuvant and adjuvant chemotherapy
  
  04:00 - 04:25 | Presenter: P Bunn
  Abstract
  
  No abstract available for this presentation
- 28254
  
  +
  
  Discussion
  
  05:40 - 06:00 | Presenter: X Cai
  Abstract
  
  No abstract available for this presentation
- 28253
  
  +
  
  The translational research of neoadjuvant therapy
  
  20:25 - 20:50 | Presenter: W Zhong
  Abstract
  
  No abstract available for this presentation
28255

+
Parallel Session 2 - New strategy for local advanced NSCLC
- 16:20 - 17:00
- 11/09/2018
- Location: Crystall Ballroom 1
- Type: Oral Session
- Track:
- 28256
  
  +
  
  Optimal RT for local advanced NSCLC
  
  05:15 - 05:40 | Presenter: M Fan
  Abstract
  
  No abstract available for this presentation
- 28257
  
  +
  
  Discussions for a Next-Generation ROS1 Inhibitor Repotrectinib and Patient-reported Outcome(PRO)
  
  05:40 - 06:00 | Presenter: J Wang
  Abstract
  
  No abstract available for this presentation
28258

+
Parallel Session 3 - SCLC: developments and challenges
- 16:20 - 17:00
- 11/09/2018
- Location: Crystall Ballroom 3
- Type: Oral Session
- Track:
- 28259
  
  +
  
  Genomic study for SCLC: Is this a waste of time?
  
  04:25 - 04:50 | Presenter: D Carbone
  Abstract
  
  No abstract available for this presentation
- 28260
  
  +
  
  Role of surgical resection and chemotherapy for T1-2N0 SCLC
  
  05:15 - 05:40 | Presenter: Z Zhang
  Abstract
  
  No abstract available for this presentation
28247

+
Plenary Session - Immunotherapy for lung cancer
- 16:20 - 17:00
- 11/09/2018
- Location: Crystal Ballroom
- Type: Oral Session
- Track:
- 28248
  
  +
  
  Walking through the maze of first line immunotherapy for advanced NSCLC
  
  08:30 - 08:55 | Presenter: F Hirsch
  Abstract
  
  No abstract available for this presentation
- 28249
  
  +
  
  PDL1 expression versus TMB: Which should we use?
  
  09:20 - 09:45 | Presenter: G Lin
  Abstract
  
  No abstract available for this presentation
- 28250
  
  +
  
  Development of immunotherapy in China
  
  09:45 - 00:10 | Presenter: Q Zhou
  Abstract
  
  No abstract available for this presentation

Session Information

ACLC 2018

IASLC Asia Conference on Lung Cancer 2018

Enter Virtual Meeting Access Code

+

Best abstracts selected from submissions 4

+

OA07 - Clinical Characterization Of ERBB2 Exon 20 Insertions and Heterogeneity of Outcomes to Afatinib in Chinese Lung Cancers

+

OA08 - Efficacy and Safety of Sintilimab Combined with 1st Line Chemotherapy in Advanced Squamous Cell Non-small Cell Lung Cancer

+

Best abstracts selected from submissions 5

+

OA09 - Preliminary Clinical Activity of Repotrectinib (TPX-0005) in Advanced ROS1 Fusion-Positive Non-Small Cell Lung Cancer

+

OA10 - CheckMate 078: Patient-Reported Outcomes (PROs) With Nivolumab vs Docetaxel in Advanced Non-Small Cell Lung Cancer (NSCLC)

+

Best abstracts selected from submissions 6

+

OA11 - First-Line Nivolumab + Ipilimumab in Asian Patients With Advanced NSCLC and High TMB (?10 mut/Mb): Results From CheckMate 227

+

OA12 - A Phase I Study of Novel Bcl-2/Bcl-xL Inhibitor APG-1252 in Patients with Advanced SCLC

+

Best abstracts selected from submissions 7

+

OA13 - High-dose Icotinib in Advanced NSCLC with EGFR 21 L858R Mutation: A Randomized, Open-Label Phase II Study

+

OA14 - Phase 2 Study: Tepotinib + Gefitinib in MET+/Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

+

Parallel Session 1 - New strategy for neoadjuvant and adjuvant therapy

+

New perspectives on neoadjuvant and adjuvant chemotherapy

+

Discussion

+

The translational research of neoadjuvant therapy

+

Parallel Session 2 - New strategy for local advanced NSCLC

+

Optimal RT for local advanced NSCLC

+

Discussions for a Next-Generation ROS1 Inhibitor Repotrectinib and Patient-reported Outcome(PRO)

+

Parallel Session 3 - SCLC: developments and challenges

+

Genomic study for SCLC: Is this a waste of time?

+

Role of surgical resection and chemotherapy for T1-2N0 SCLC

+

Plenary Session - Immunotherapy for lung cancer

+

Walking through the maze of first line immunotherapy for advanced NSCLC

+

PDL1 expression versus TMB: Which should we use?

+

Development of immunotherapy in China

Stay Connected